Trelagliptin and Omarigliptin represent a significant advancement in diabetes management as once-weekly DPP-4 inhibitors. They promise improved patient compliance, simplified regimens, and enhanced glycemic control. While offering cost-effective and practical solutions for diabetes care, especially in resource-limited settings, challenges like long-term safety data must be addressed for broader adoption.
healthinfo 